Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: The ADAGIO study

Filomena Mazzeo, Lionel Duck, Eric Joosens, Luc Dirix, Christian Focan, Frédéric Forget, Sabina De Geest, Katja Muermans, Marie Anne Van Lierde, Karen Macdonald, Ivo Abraham, Jacques De Grève

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Aim: To determine imatinib nonadherence rates in patients with gastrointestinal tumors (GIST) over 90 days. Patients and Methods: A prospective 90-day observational, open-label, multicenter study was carried out of 28 evaluable GIST patients on imatinib. Nonadherence behavior was measured using a 4-item patient interview. Clinicians, patients, and collaterals rated perceived patient adherence on a 0-100 VAS scale. Results: Nonadherence rates in the 4 weeks prior to baseline and follow-up were 29% (95% CI=26-32) and 24% (95% CI=21-27, p>0.05). Mean VAS ratings of perceived adherence ranged from 952±102 to 973±4.8 (p>0.05 for time and source of rating). Correlations between perceptions of and actual adherence behavior were negative. Conclusion: In this first study on imatinib nonadherence in GIST patients, rates were similar to those observed in patients with chronic myeloid leukemia, higher than clinically expected and exceeding meta-analytic estimates for cancer. Nonadherence rates were consistent across the 90-day period. Nonadherence behavior should be assessed by clinicians.

Original languageEnglish (US)
Pages (from-to)1407-1410
Number of pages4
JournalAnticancer research
Issue number4
StatePublished - Apr 2011


  • ADAGIO study
  • Adherence
  • Gastrointestinal stromal tumor
  • Imatinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: The ADAGIO study'. Together they form a unique fingerprint.

Cite this